PuSH - Publikationsserver des Helmholtz Zentrums München

Targeting innate and adaptive immune responses to cure chronic HBV infection.
Gastroenterology 156, 325-337 (2018)
DOI
online verfügbar vsl. 10/2019 
Fewer than 1% of chronic hepatitis B virus infections per year are cured with antiviral treatment. This creates a need for long-term treatment, which poses challenges for patients and health systems. Because cure is accompanied by recovery of antiviral immunity, a combination of direct-acting antiviral agents and immunotherapy are likely to be required. Extensive efforts have been made to identify determinants of the failed immune response to hepatitis B virus in patients with chronic infection. We review mechanisms of immune dysfunction in patients with chronic hepatitis B virus infection, immunotherapy strategies in development, and the challenges associated with successful implementation of immunotherapy.
Altmetric
Weitere Metriken?
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Drug ; Hbsag ; Vaccine ; Inflammation; Hepatitis-b-virus; Cd8(+) T-cells; Adoptive Transfer; Viral-hepatitis; Surface-antigen; Hepatocellular-carcinoma; Programmed Death-1; Liver; Replication; Hepatocytes
ISSN (print) / ISBN 0016-5085
e-ISSN 1528-0012
Zeitschrift Gastroenterology
Quellenangaben Band: 156, Heft: 2, Seiten: 325-337 Artikelnummer: , Supplement: ,
Verlag Elsevier ; Saunders
Verlagsort 1600 John F Kennedy Boulevard, Ste 1800, Philadelphia, Pa 19103-2899 Usa
Begutachtungsstatus peer-reviewed